Project description DEENESFRITPL Non-invasive cardiac arrhythmia ablation with proton therapy Heart arrhythmia affects millions of people and the numbers are expected to grow due to the aging populations and lifestyle changes. The current standard catheter ablation procedure requires hospitalisation and has a high risk of complications, such as bleeding, infection, and damage to heart valves or blood vessels. Swiss EBAMed developed a non-invasive device, Cardio-kit, for the treatment of heart arrhythmia using proton therapy. It monitors the heart in real-time and automatically adjusts the stop/go signal to the proton therapy machine based on the cardiac cycle, providing accurate, effective and safe treatment of the moving target within the heart. The EU-funded Cardio-kit project will enable optimisation of the Cardio-kit hardware and software and start of clinical validation procedures necessary for commercialisation in Europe. Show the project objective Hide the project objective Objective Heart arrhythmia is a major worldwide public health problem, accounting for 15–20% of all deaths. Heart arrhythmias affects over 15 million people in Europe and North America and this number is expected to double in the next 50 years due to the aging population and lifestyle changes. Catheter ablation is the current gold standard for heart arrhythmia treatment. The surgical procedure is performed by introducing a catheter under anaesthesia into the heart chambers, to ablate selected target regions by applying heat. This invasive procedure requires patient hospitalization, a staff of 10 doctors, and has a high risk of complications, such as bleeding, infection and damage to heart valves and blood vessels. EBAMed developed Cardio-kit, a non-invasive medical device for heart arrhythmia treatment using proton therapy. Cardio-kit is a plug & play system that can be integrated into any existing proton therapy machine. Cardio-kit enables monitoring of heart movements in real-time, and automatically adjust the Stop/Go signal to the proton therapy machine based on the cardiac cycle in which to intervene. Cardio-kit ensures an accurate, effective and safe treatment of the moving target within the heart at the right time. In this way, Cardio-kit facilitates an out-patient procedure, as it does not require any hospitalization or sedation. The procedure is quick, safe, painless and suitable for any age and health condition patient with no side-effects.The EIC funding will enable EBAMed to optimize the Cardio-kit hardware and software components, and to perform all the clinical validation activities necessary to obtain CE Mark and start commercialization in Europe. Fields of science medical and health sciencesclinical medicinecardiologycardiovascular diseasescardiac arrhythmianatural sciencescomputer and information sciencessoftwaremedical and health scienceshealth sciencespublic healthmedical and health sciencesclinical medicinesurgerysurgical proceduresmedical and health sciencesclinical medicineanaesthesiology Keywords Proton therapy cardiac arrhytmias machine learning real-time data processing heart motion tracking Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Topic(s) EIC-SMEInst-2018-2020 - SME instrument Call for proposal H2020-EIC-SMEInst-2018-2020 See other projects for this call Sub call H2020-EIC-SMEInst-2018-2020-3 Funding Scheme SME-2 - SME instrument phase 2 Coordinator EBAMED SA Net EU contribution € 2 405 025,00 Address Avenue de secheron 15 1202 Geneve Switzerland See on map Region Schweiz/Suisse/Svizzera Région lémanique Genève Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 1 627 000,00
